Your browser is no longer supported. Please, upgrade your browser.
Settings
ARPO Aerpio Pharmaceuticals, Inc. daily Stock Chart
ARPO [NASD]
Aerpio Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.46 Insider Own24.32% Shs Outstand40.59M Perf Week6.85%
Market Cap32.50M Forward P/E- EPS next Y- Insider Trans- Shs Float30.72M Perf Month20.00%
Income-18.70M PEG- EPS next Q-0.13 Inst Own24.50% Short Float0.12% Perf Quarter14.68%
Sales- P/S- EPS this Y-87.10% Inst Trans11.21% Short Ratio0.05 Perf Half Y50.00%
Book/sh0.81 P/B0.96 EPS next Y- ROA-43.80% Target Price1.00 Perf Year-29.73%
Cash/sh0.83 P/C0.94 EPS next 5Y- ROE-47.60% 52W Range0.42 - 1.12 Perf YTD25.10%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-30.36% Beta-
Dividend %- Quick Ratio13.30 Sales past 5Y- Gross Margin- 52W Low85.71% ATR0.09
Employees12 Current Ratio13.30 Sales Q/Q- Oper. Margin- RSI (14)61.63 Volatility9.36% 11.73%
OptionableNo Debt/Eq0.00 EPS Q/Q53.90% Profit Margin- Rel Volume0.72 Prev Close0.80
ShortableYes LT Debt/Eq0.00 EarningsMar 16 BMO Payout- Avg Volume728.22K Price0.78
Recom3.00 SMA2011.07% SMA5027.81% SMA20026.48% Volume521,577 Change-2.49%
Jul-23-18Initiated Needham Buy $10
May-21-20 12:00PM  Aerpio Pharmaceuticals, Inc. (ARPO) Upgraded to Strong Buy: Here's Why Zacks
08:01AM  New Strong Buy Stocks For May 21st Zacks
May-13-20 07:40AM  The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter Benzinga +25.14%
May-12-20 04:30PM  Aerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease (IBD) Product Candidate GB004 (formerly AKB-4924) GlobeNewswire
May-11-20 11:30AM  Is Aerpio Pharmaceuticals (ARPO) Stock Outpacing Its Medical Peers This Year? Zacks
May-07-20 08:00AM  Aerpio Reports First Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
May-06-20 05:45PM  Aerpio Pharmaceuticals, Inc. (ARPO) Gains As Market Dips: What You Should Know Zacks
Apr-24-20 07:24AM  New Strong Buy Stocks for April 24th Zacks +13.83%
Apr-22-20 05:50PM  Aerpio Pharmaceuticals, Inc. (ARPO) Gains But Lags Market: What You Should Know Zacks
11:30AM  Has Aerpio Pharmaceuticals (ARPO) Outpaced Other Medical Stocks This Year? Zacks
Apr-20-20 10:46AM  New Strong Buy Stocks For April 20th Zacks +17.79%
Apr-16-20 08:39AM  Immunovant (IMVT) Catches Eye: Stock Jumps 5% Zacks +14.32%
Apr-09-20 06:35AM  Does Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO) Have A High Beta? Simply Wall St.
Apr-08-20 12:00PM  Aerpio Pharmaceuticals, Inc. (ARPO) Moves to Strong Buy: Rationale Behind the Upgrade Zacks
Mar-16-20 08:00AM  Aerpio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update GlobeNewswire -7.14%
Mar-12-20 05:00PM  Aerpio Pharmaceuticals to Report Year Ended December 31, 2019 Financial Results on Monday, March 16, 2020 GlobeNewswire
Feb-09-20 09:49AM  Those Who Purchased Aerpio Pharmaceuticals (NASDAQ:ARPO) Shares A Year Ago Have A 80% Loss To Show For It Simply Wall St.
Feb-07-20 06:20PM  Aerpio Pharmaceuticals Presents Data from Fifth Patient Cohort Showing Potential of Topical Ocular Formulation of AKB-9778 Product Candidate When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension Business Wire
Jan-08-20 08:43AM  Topical Ocular Formulation of Aerpio Pharmaceuticals AKB-9778 Product Candidate Produced IOP Lowering with Minimal Hyperemia When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension in Phase 1b Trial Business Wire -6.94%
Dec-22-19 05:08PM  Hedge Funds Are Buying Aerpio Pharmaceuticals, Inc. (ARPO) Insider Monkey
Nov-11-19 06:59AM  Here's Why We're A Bit Worried About Aerpio Pharmaceuticals's (NASDAQ:ARPO) Cash Burn Situation Simply Wall St.
Nov-07-19 07:00AM  Aerpio Reports Third Quarter 2019 Financial Results and Provides Business Update Business Wire
Oct-21-19 11:09AM  Cincinnati firms stock jumps amid C-suite shakeup, possibility of sale or merger American City Business Journals +15.08%
05:00AM  Aerpio Pharmaceuticals Announces Review of Strategic Alternatives Business Wire
Oct-10-19 02:30PM  Aerpio Pharmaceuticals Announces Interim Results from its Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle Glaucoma Business Wire -8.03%
Oct-09-19 09:00AM  All You Need to Know About Aerpio Pharmaceuticals, Inc. (ARPO) Rating Upgrade to Buy Zacks
Aug-14-19 04:59PM  Cincinnati stocks hammered as Dow suffers fourth-biggest drop American City Business Journals
Aug-08-19 07:00AM  Aerpio Reports Second Quarter 2019 Financial Results and Provides Business Update Business Wire
Jul-05-19 01:09PM  This Cincinnati stock gained 457% in the first half of 2019: SLIDESHOW American City Business Journals
Jun-10-19 07:00AM  Aerpio Initiates Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle Glaucoma Business Wire
May-14-19 12:36PM  Wall Street Sees 3 Falling Knives Rebounding Within 52 Weeks GuruFocus.com
May-09-19 07:00AM  Aerpio Reports First Quarter 2019 Financial Results and Provides Business Update Business Wire
May-02-19 07:00AM  Aerpio Pharmaceuticals Presents Data Showing Potential of AKB-9778, a VE-PTP Inhibitor/Tie2 Activator, to Lower Intra-ocular Pressure in Human Subjects Business Wire
Apr-25-19 07:00AM  Aerpio Pharmaceuticals to Present Data Demonstrating Role of VE-PTP in Conventional Outflow Homeostasis and the Potential of AKB-9778, a VE-PTP Inhibitor/Tie2 Activator, as a Treatment for Open-Angle Glaucoma Business Wire
Apr-09-19 09:00AM  Aerpio Pharmaceuticals, Inc. (ARPO) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Apr-05-19 04:05PM  Aerpio Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference Business Wire
Mar-18-19 03:05PM  Aerpio Pharmaceuticals stock plummets after failed trial of diabetic retinopathy treatment MarketWatch -71.29%
01:41PM  Greater Cincinnati pharma firms stock plummets American City Business Journals
07:00AM  Aerpio Pharmaceuticals Announces Results From TIME-2b Study of AKB-9778 in Diabetic Retinopathy Business Wire
Mar-07-19 06:48AM  Aerpio Pharmaceuticals Inc (ARPO) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Mar-05-19 07:00AM  Aerpio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update Business Wire +5.94%
Feb-26-19 07:00AM  Aerpio Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Tuesday, March 5, 2019 Business Wire +10.27%
Jan-22-19 08:39AM  Aerpio (ARPO) Jumps: Stock Rises 7.8% Zacks +7.88%
Jan-17-19 07:00AM  Aerpio Pharmaceuticals Announces Completion of Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathy Business Wire +5.16%
Nov-28-18 04:31PM  Cincinnati stocks soar as Dow Jones posts one of its five biggest gains ever American City Business Journals +6.67%
Nov-14-18 07:30AM  Recent Analysis Shows Atlas Financial, Royal Dutch Shell, Vaalco Energy, Myovant Sciences, Aerpio Pharmaceuticals, and Wheeler Real Estate Investment Trust Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-08-18 07:00AM  Aerpio Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference Business Wire
Nov-07-18 07:00AM  Aerpio Reports Third Quarter 2018 Financial Results and Provides Business Update Business Wire
Oct-31-18 07:00AM  Aerpio Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Wednesday, November 7, 2018 Business Wire
Oct-25-18 08:00AM  Aerpio Pharmaceuticals Announces Presentation of Renal Function Data from TIME-2 Study of AKB-9778 in Diabetic Retinopathy Patients at American Society of Nephrology Kidney Week 2018 Business Wire +12.23%
Sep-24-18 07:00AM  Aerpio Pharmaceuticals to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference Business Wire -5.60%
Aug-30-18 07:00AM  Aerpio Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC Business Wire
Aug-16-18 09:37AM  The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait Benzinga +8.71%
Aug-14-18 07:00AM  Aerpio Reports Second Quarter 2018 Financial Results and Provides Business Update Business Wire
06:30AM  Aerpio Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-07-18 07:00AM  Aerpio Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Tuesday, August 14, 2018 Business Wire -8.48%
Jul-23-18 07:24PM  [$$] Gossamer Bio Bulks Up With $230 Million Series B The Wall Street Journal
Jun-26-18 09:18AM  Aerpio Pharmaceuticals Announces Uplisting to Nasdaq Capital Market and Pricing of $45.0 Million Public Offering of Common Stock Business Wire -14.29%
Jun-25-18 04:01PM  Aerpio Pharmaceuticals Announces Proposed Public Offering of Common Stock and Uplisting to Nasdaq Capital Market Business Wire +8.33%
07:00AM  Aerpio Announces Exclusive License Agreement with Gossamer Bio for AKB-4924, a First in Class Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease Business Wire
May-31-18 07:00AM  Aerpio Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference Business Wire
May-22-18 08:52AM  Aerpio Announces Initiation of Dosing in a Phase 1a, Multiple-Ascending Dose Study of AKB-4924, a Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease Business Wire
May-15-18 06:15PM  Aerpio Pharmaceuticals Announces Nomination of Industry Veteran Cheryl Cohen to Board of Directors Business Wire +8.00%
07:00AM  Aerpio Reports First Quarter 2018 Financial Results and Provides Company Update Business Wire
May-04-18 11:30AM  Aerpio Announces Presentations on Novel Treatments for Glaucoma and Retinal Diseases at ARVO 2018 Annual Meeting Business Wire
Apr-21-18 04:58PM  HC Wainwright Says Aerpio Pharma Flies Under The Radar Due To OTC Listing, Projects 150% Upside Benzinga
Mar-20-18 07:10AM  Aerpio Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference Business Wire
Mar-15-18 07:00AM  Aerpio Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference Business Wire
Mar-13-18 07:00AM  Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update Business Wire
Mar-07-18 07:00AM  Aerpio Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Tuesday, March 13, 2018 Business Wire
Mar-06-18 07:00AM  Aerpio Pharmaceuticals to Present at the Cowen 38th Annual Health Care Conference Business Wire
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2b clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.